• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cytokinetics Incorporated

    8/7/25 4:02:46 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYTK alert in real time by email
    S-8 1 d77672ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 7, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

     

     

    CYTOKINETICS, INCORPORATED

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   94-3291317

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    350 Oyster Point Boulevard

    South San Francisco, CA 94080

    (Address of principal executive offices)

     

     

    AMENDED AND RESTATED 2004 EQUITY INCENTIVE PLAN

    (Full title of the plan)

     

     

    Robert I. Blum

    President and Chief Executive Officer

    Cytokinetics, Incorporated

    350 Oyster Point Boulevard

    South San Francisco, CA 94080

    (650) 624-3000

    (Name, address, and telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 5,000,000 shares of the Common Stock to be issued pursuant to the Amended and Restated 2004 Equity Incentive Plan (the “EIP”). The shares of the Common Stock previously reserved for issuance under the EIP were registered on the Registrant’s Registration Statements on Form  S-8 previously filed with the Securities and Exchange Commission (the “SEC”) on May 4, 2004 (File No. 333-115146), June 20, 2005 (File No.  333-125973), April 14, 2006 (File No.  333-133323), February  28, 2007 (File No. 333-140963), March 14, 2008 (File No. 333-149713), August 7, 2008 (File No.  333-152850), August 6, 2009 (File No.  333-161116), August 4, 2010 (File No.  333-168520), August 5, 2011 (File No.  333-176089), August 6, 2012 (File No.  333-183091), August 7, 2013 (File No.  333-190458), August  5, 2015 (File No. 333-206101), November 3, 2017 (File No. 333-221348), March 4, 2020 (File No.  333-236889), May 29, 2020 (File No.  333-238786), May 13, 2021 (File No.  333-256054), November 5, 2021 (File No.  333-260840), May 31, 2022 (File No.  333-265316), and March 1, 2023 (File No. 333-270182), (collectively, the “Prior Registration Statements”).

    This Registration Statement on Form S-8 relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E to Form S-8 regarding Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the EIP are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    ITEM 8. EXHIBITS

     

    Exhibit

    Number

      Description
     4.1(1)   Amended and Restated Certificate of Incorporation.
     4.2(2)   Amended and Restated Bylaws.
     4.3(3)   Certificate of Amendment of Amended and Restated Certificate of Incorporation.
     4.4(4)   Certificate of Amendment of Amended and Restated Certificate of Incorporation.
     4.5(5)   Certificate of Amendment of Amended and Restated Certificate of Incorporation.
     4.6(6)   Certificate of Amendment of Amended and Restated Certificate of Incorporation.
     4.7*   Certificate of Amendment of Amended and Restated Certificate of Incorporation
     4.8(7)   Specimen Common Stock Certificate.
     5.1*   Opinion of Cooley LLP.
    23.1*   Consent of Independent Registered Public Accounting Firm.
    23.2*   Consent of Cooley LLP (included in Exhibit 5.1).
    24.1*   Power of Attorney (included on the signature page of this Form S-8).
    99.1(8)   Amended and Restated 2004 Equity Incentive Plan.
    107*   Filing Fee Table.

     

    *

    Filed herewith

    (1)

    Incorporated by reference to Exhibit 3.1 to the Company’s registration statement on Form S-3, registration number 333-174869, filed with the Securities and Exchange Commission on June 13, 2011.

    (2)

    Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on November 17, 2023.

    (3)

    Incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 4, 2011.

    (4)

    Incorporated by reference to Exhibit 5.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 25, 2013.

    (5)

    Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 20, 2016.

    (6)

    Incorporated by reference to Exhibit 3.5 to the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on August 3, 2023.

    (7)

    Incorporated by reference to Exhibit 4.1 to the Company’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 9, 2007.

    (8)

    Incorporated by reference to Appendix A of the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on April 10, 2025.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on this seventh day of August, 2025.

     

    CYTOKINETICS, INCORPORATED
    By:  

    /s/ Robert I. Blum

      Robert I. Blum
     

    President and Chief Executive Officer

    (Principal Executive Officer)

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert I. Blum, Sung Lee and John Faurescu jointly and severally, as his or her attorneys-in-fact, with full power of substitution in each, for him or her in any and all capacities to sign any amendments to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitutes, may do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.


    Signature    Title    Date

    /s/ Robert I. Blum

         
    Robert I. Blum   

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

       August 7, 2025

    /s/ Sung Lee

         
    Sung Lee   

    Executive Vice President, Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

       August 7, 2025

    /s/ John T. Henderson

       Chairman of the Board of Directors    August 7, 2025
    John T. Henderson, M.B., Ch. B.      

    /s/ Muna Bhanji

       Director    August 7, 2025
    Muna Bhanji      

    /s/ Robert A. Harrington

       Director    August 7, 2025
    Robert A. Harrington, M.D.      

    /s/ Edward M. Kaye

       Director    August 7, 2025
    Edward M. Kaye, M.D.      

    /s/ Robert E. Landry

       Director    August 7, 2025
    Robert E. Landry      

    /s/ B. Lynne Parshall

       Director    August 7, 2025
    B. Lynne Parshall, Esq.      

    /s/ Wendell Wierenga

       Director    August 7, 2025
    Wendell Wierenga, Ph. D.      

    /s/ Nancy J. Wysenski

       Director    August 7, 2025
    Nancy J. Wysenski      
    Get the next $CYTK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYTK

    DatePrice TargetRatingAnalyst
    7/30/2025Mkt Perform
    Raymond James
    4/24/2025$55.00Overweight
    Barclays
    2/7/2025$86.00Buy
    Citigroup
    1/22/2025$80.00Buy
    Stifel
    11/8/2024$80.00Outperform
    RBC Capital Mkts
    8/13/2024$85.00 → $60.00Buy → Neutral
    Goldman
    1/24/2024$61.00 → $92.00Buy → Neutral
    UBS
    1/5/2024$60.00 → $90.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $CYTK
    SEC Filings

    View All

    SEC Form 10-Q filed by Cytokinetics Incorporated

    10-Q - CYTOKINETICS INC (0001061983) (Filer)

    8/7/25 4:30:30 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Cytokinetics Incorporated

    S-8 - CYTOKINETICS INC (0001061983) (Filer)

    8/7/25 4:02:46 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CYTOKINETICS INC (0001061983) (Filer)

    8/7/25 4:01:47 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James resumed coverage on Cytokinetics

    Raymond James resumed coverage of Cytokinetics with a rating of Mkt Perform

    7/30/25 7:32:47 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Cytokinetics with a new price target

    Barclays initiated coverage of Cytokinetics with a rating of Overweight and set a new price target of $55.00

    4/24/25 7:43:15 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Cytokinetics with a new price target

    Citigroup initiated coverage of Cytokinetics with a rating of Buy and set a new price target of $86.00

    2/7/25 8:37:05 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of December 26, 2025 PDUFA Date Primary Results from MAPLE-HCM to be Presented in a Hot Line Session at the European Society of Cardiology Congress 2025 ~$1.0 Billion in Cash, Cash Equivalents and Investments as of June 30, 2025 SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the second quarter of 2025. "Following solid progress in the first half of the year, we are looking forward to several key corpor

    8/7/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics to Announce Second Quarter Results On August 7, 2025

    SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report second quarter results on August 7, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com or directly at the following link: Cytokinetics Q2 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics' we

    7/24/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in June and July 2025 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the g

    7/18/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Blum Robert I sold $192,100 worth of shares (5,000 units at $38.42), decreasing direct ownership by 1% to 383,108 units (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    8/15/25 4:23:29 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP Research & Development Malik Fady Ibraham exercised 2,000 shares at a strike of $10.60 and sold $72,680 worth of shares (2,000 units at $36.34) (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    8/5/25 6:28:50 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Blum Robert I sold $182,250 worth of shares (5,000 units at $36.45), decreasing direct ownership by 1% to 388,108 units (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    7/31/25 4:38:53 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Leadership Updates

    Live Leadership Updates

    View All

    Cytokinetics Names Robert E. Landry to Board of Directors

    Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. for 11 years. "We are pleased to have Bob join our Board as we approach a key shareholder value inflection point for the company and prepare for the potential approval and launch of our first medici

    2/11/25 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alltrna Announces Updates to Its Board of Directors

    Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

    7/17/24 8:00:00 AM ET
    $APRE
    $CYTK
    $EVLO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)

    Super Micro Computer and Deckers Outdoor Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, March 1, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed

    3/1/24 6:47:00 PM ET
    $AIT
    $AL
    $APPS
    Industrial Specialties
    Consumer Discretionary
    Diversified Commercial Services
    Multi-Sector Companies

    $CYTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cytokinetics Incorporated

    SC 13G - CYTOKINETICS INC (0001061983) (Subject)

    11/14/24 1:28:31 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

    SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)

    11/12/24 2:21:36 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

    SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)

    11/12/24 9:55:17 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Financials

    Live finance-specific insights

    View All

    Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA Scheduled for September Ahead of December 26, 2025 PDUFA Date Primary Results from MAPLE-HCM to be Presented in a Hot Line Session at the European Society of Cardiology Congress 2025 ~$1.0 Billion in Cash, Cash Equivalents and Investments as of June 30, 2025 SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the second quarter of 2025. "Following solid progress in the first half of the year, we are looking forward to several key corpor

    8/7/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics to Announce Second Quarter Results On August 7, 2025

    SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report second quarter results on August 7, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com or directly at the following link: Cytokinetics Q2 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics' we

    7/24/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

    PDUFA Date for Aficamten in Obstructive HCM Extended by FDA to December 26, 2025 Topline Results from MAPLE-HCM Expected in May Enrollment Completed in ACACIA-HCM; Topline Results Expected in 1H 2026 ~$1.1 Billion in Cash, Cash Equivalents and Investments as of March 31, 2025 SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the first quarter of 2025. "In the first quarter, we made progress towards commercial readiness and advanced our specialty cardiology pipeline," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "Recently, our PDUFA date for aficamte

    5/6/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care